• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Athersys Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

    12/22/23 5:09:11 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHX alert in real time by email
    athx20231222_8k.htm
    false 0001368148 0001368148 2023-12-20 2023-12-20
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): December 20, 2023
     
    ATHERSYS, INC.
    ATHERSYS, INC / NEW
    (Exact Name of Registrant as Specified in Charter) 
     

     
    Delaware
    001-33876
    20-4864095
    (State or Other Jurisdiction
    of Incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
     
     
    3201 Carnegie Avenue,  Cleveland,   Ohio
     
    44115-2634
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (216) 431-9900
     
     
    (Former Name or Former Address, if Changed Since Last Report)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol
    Name of each exchange on which registered
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company  ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     


     
     

     
     
    Item 2.05         Costs Associated with Exit or Disposal Activities.
     
    On December 15, 2023, Athersys, Inc. (the “Company”) terminated four of its employees. Effective December 31, 2023, the Company anticipates terminating its remaining employees, including Daniel A. Camardo, the Company’s Chief Executive Officer (“CEO”), and Maia Hansen, the Company’s Chief Operating Officer (“COO”). The Company anticipates that some of the terminated employees may continue to advise the Company on a consulting basis.
     
    The Company estimates that it will incur approximately $0.360 million of one-time pre-tax cash charges related to the employee terminations, consisting of employee severance and other one-time termination benefits. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the terminations.
     
    Item 5.02         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    In connection with the employee terminations discussed in Item 2.05 of this Current Report on Form 8-K, the Company anticipates that Mr. Camardo, the Company’s CEO, and Ms. Hansen, the Company’s COO, will depart from the Company on December 31, 2023. Mr. Camardo and Ms. Hansen may continue to advise the Company on a consulting basis following that date, pursuant to the terms of a future consulting agreement. The employment agreements of Mr. Camardo and Ms. Hansen will be terminated effective December 31, 2023, including any severance benefits to which they were entitled under those agreements.
     
    In exchange for their execution of a customary release of claims (“Release”) on December 20, 2023 in favor of the Company and agreement to the termination of their employment agreements, the Company agreed to pay Mr. Camardo and Ms. Hansen one-time termination benefits, consisting of one month of salary and the value of two months of continuation of health care cover pursuant to the Consolidated Omnibus Budget Reconciliation Act, or COBRA.
     
    A copy of the Release will be filed as an exhibit to the Company’s next periodic report or other applicable filing, and the description of the Release is qualified in its entirety by reference to such exhibit.
     
    Cautionary Note Regarding Forward-Looking Statements
     
    This Current Report on Form 8-K contains statements that are, or may be deemed, “forward-looking statements.” Forward-looking statements generally use forward-looking words, such as “may,” “will,” “could,” “should,” “would,” “project,” “believe,” “anticipate,” “expect,” “estimate,” “continue,” “potential,” “plan,” “forecast” and other words that convey the uncertainty of future events or outcomes. Forward-looking statements include, but are not limited to, information concerning the following: possible proceedings that may be brought by third parties in connection with the employee terminations discussed above; the impact and timing of any cost-savings measures and employee departures; the impact of litigation and regulatory proceedings; expectations regarding financial performance, strategic and operational plans, and other related matters; and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” section of the Annual Report on Form 10-K for its 2022 fiscal year. These forward-looking statements are not guarantees of the Company’s future performance and involve risks, uncertainties, estimates, and assumptions that are difficult to predict and may be outside of the Company’s control. Therefore, the actual outcomes and results may differ materially from those expressed in or contemplated by the forward-looking statements. Any forward-looking statement speaks only as of the date of this Current Report on Form 8-K. Except as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and investors are cautioned not to rely upon them unduly.
     
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: December 22, 2023
     
    ATHERSYS, INC.
         
     
    By:
    /s/ Daniel Camardo
       
    Daniel Camardo
    Chief Executive Officer and Duly Authorized Officer
     
     
    Get the next $ATHX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHX

    DatePrice TargetRatingAnalyst
    11/19/2021$1.25Buy → Neutral
    B of A Securities
    11/19/2021Buy → Neutral
    BofA Securities
    More analyst ratings

    $ATHX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

      Athersys, Inc. (OTC:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating additional patients would need to be added to the trial to achieve statistical significance with a primary endpoint of mRS Shift Analysis at Day 365. Completed warrant exercise inducement generating gross proceeds of $3.

      11/16/23 8:30:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

      Athersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license. On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants

      10/16/23 4:52:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

      The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the s

      10/10/23 8:30:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    SEC Filings

    See more
    • Athersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

      1/8/24 7:31:19 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Athersys Inc.

      25-NSE - ATHERSYS, INC / NEW (0001368148) (Subject)

      12/27/23 9:01:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

      8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

      12/22/23 5:09:11 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Leadership Updates

    Live Leadership Updates

    See more
    • Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

      Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commercialization of healthcare innovations. Under her leadership, Wave Strategy has bridged early-stage t

      8/11/23 8:00:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Murchinson Issues Letter to Fellow Shareholders Regarding the Urgent Need for Boardroom Change at Nano Dimension

      Believes the Stern-Controlled Board's Decision to Challenge Our Special Meeting Demand – Without Any Valid Justification – Reinforces the Need for Objective and Independent Perspectives in the Boardroom Contends the Company is Making Misleading Claims About Murchinson to Distract from Mr. Stern Having Presided Over a More Than 77% Share Price Decline Since Becoming Chairman Puts Forward Proposals to Remove Four Incumbents and Appoint Two Highly Qualified, Independent Director Candidates with Sorely Needed Capital Allocation Acumen and Corporate Governance Expertise Sees a Clear Opportunity to Optimize Nano Dimension's Overcapitalized Balance Sheet, Explore Strategic Options to Maximize V

      2/2/23 5:25:00 PM ET
      $ATHX
      $IMMR
      $NNDM
      $SSYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer peripheral equipment
      Technology
    • Athersys Appoints Joseph Nolan to Its Board of Directors

      Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph "Joe" Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent. "Joe is a strong addition to our Board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations. His understanding of th

      1/5/23 4:33:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Athersys downgraded by B of A Securities with a new price target

      B of A Securities downgraded Athersys from Buy to Neutral and set a new price target of $1.25

      11/19/21 8:21:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys downgraded by BofA Securities

      BofA Securities downgraded Athersys from Buy to Neutral

      11/19/21 7:12:53 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care